SARC Developmental Therapeutics Committee Update Chand Khanna Open Science: Biology to Therapy” SARC Developmental Therapeutics Committee Update Chand.

Slides:

Advertisements

Similar presentations

PLENARY SESSION Fall Group Meeting Miami, FL November 13, 2010.

Advertisements

“It is the responsibility of those of us involved in today’s biomedical research enterprise to translate the remarkable scientific innovations we are witnessing.

December 14, FDA Advisory Committee for Pharmaceutical Science Nonclinical Studies Subcommittee Efficient advancement to clinical trials Jack A.

Raphael Pollock, MD, PhD Principal Investigator

SARC Business Meeting November Trial Update SARC 001 Gleevec –Closed to accrual –Outstanding data –Requests SARC 002 STS/gem-txt –Closed to accrual.

Brian C. Springer, MHA Executive Director Siteman Cancer Center Barnes-Jewish Hospital & Washington U. School of Med CCSG-CTSA Interactions Michael Bertram,

National Cancer Institute U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health NCI Perspective on Informatics and Clinical Decision.

Cancer Nanotechnology: New Opportunities for Targeted Therapies FDA Public Meeting October 10, 2006 Piotr Grodzinski, Ph.D. Director, Nanotechnology for.

Interagency Oncology Task Force (IOTF) Research and Regulatory Review Fellowships

School of Medicine Shared Resource Facilities The School of Medicine provides direct support and oversight to 21 SOM shared resource facilities. Their.

Clinical Trials with SARC We’re here to help.. What can SARC do for you? Provide help developing a research idea Provide help with contacting pharma Provide.

N “If you bring the appropriate people together in constructive ways with good information, they will create authentic visions and sustainable responses.

Dr Stewart Hay, CEO | | (03) www.therapeuticinnovation.com.au.

NCI Review of the Clinical Trials Process 6 th Annual National Forum on Biomedical Imaging in Oncology James H. Doroshow M.D. April 7, 2005 Bethesda, Maryland.

Partnering with Federal Labs: A Panel Discussion FLC Mid-Atlantic Region Annual Meeting October 24, 2007.

1 FDA Regulation of Cell Therapy Celia M.Witten, Ph.D., M.D. Director, Office of Cellular, Tissue, and Gene Therapies Fourth Annual Translational Stem.

Progress in the RNOH-IOMS Joint Academic Strategy David Marsh Professor of Clinical Orthopaedics, Institute of Orthopaedics and Musculoskeletal Science.

SARC studies: an overview

MUSC RESEARCH OPERATIONS: NURTURING THE CULTURE OF DISCOVERY AND TRANSLATIONAL SCIENCES Stephen M. Lanier, Ph.D. FACULTY RESEARCH ORIENTATION Collaborative.

SARC Initially the North American Consortium of CTOS 501.c.3 organization Incorporated November 2003.

How can we work together? Partnering with Industry: An Investigator’s Perspective Robert L. Coleman, MD M. D. Anderson Cancer Center.

The Cancer Systems Biology Consortium (CSBC)

Iván D Vélez MD PhD. Malaria ROL OF INVESTIGATORS  Politicians,  Health authorities  Pharmaceutical industry  Pipeline and deliver products for.

Translational Genomics Research Institute | The Sarcoma Data Portal: Making High Content Sarcoma Datasets Available For All Users Jonathan.

Academic-Industry Partnership Symposium Presented by: Blank Rome LLP

CTOS IS TEN YEARS OLD SARC IS TWO YEARS OLD Happy Birthday, CTOS, SARC.

Vaccine Quo Vadis? 20 July 2010 Alan Bernstein, O.C., Ph.D. Executive Director, Global HIV Vaccine Enterprise.

Cancer Centers In Clinical Trials Sandrine Marreaud Head of Medical Department.

6/4/20161 Commitment & Efforts Toward Translational Science Subtitle Placeholder.

Kim Witmer Senior Vice President Chief Financial Officer Michael Nunn, Ph.D. Executive Director Research Development.

Initiating phase 1 clinical trials in pediatric oncology National Cancer Institute Perspective Barry Anderson, MD, PhD Pediatric Section Cancer Therapy.

THE MURDOCK Study: A Rich Data Resource for Biomarker Discovery and Validation Brian D. Bennett 1, Jessica D. Tenenbaum 1, Victoria Christian 1, Melissa.

Transforming the CTRI and UCSD: From Silo to Collaboration Gary S. Firestein, M.D.

The 2005 Chawla-Rosenfeld Symposium on Developmental Therapeutics for Sarcoma Introduction George D. Demetri, MD Dana-Farber Cancer Institute Harvard Medical.

Dinutuximab (ch14.18) for children with high-risk neuroblastoma

The SARC Sarcoma SPORE: A Unique Collaborative (Ad)venture Raphael E. Pollock, MD, PhD Department of Surgical Oncology Division of Surgery University of.

Why Write A Grant? Elaine M. Hylek, MD, MPH Professor of Medicine Associate Director, Education and Training Division BU CTSI Section of General Internal.

SARC Individual and Institutional Participation 2013.

The Regulatory Science of Regenerative Medicine Celia M. Witten, Ph.D., M.D., Director Office of Cellular, Tissue and Gene Therapies Center for Biologics.

Research in the Office of Cellular, Tissue and Gene Therapies: Vision and Overview Jesse Goodman, M.D., M.P.H. Director, Center for Biologics Evaluation.

CTEP Visiting Physician Externship Coordinator: Igor Espinoza-Delgado, M.D. NCI CTEP Investigational Drug Branch

SARC Restructuring. SARC Strategic Plan  Mission  Given there is no successful structure in the US to provide platform to make progress in the diagnosis.

Creating the Path for Innovative New Therapies Raymond L. Woosley, MD, PhD President, The Critical Path Institute.

Center for Biologics Evaluation and Research, FDA Site Visit Introduction Kathryn M. Carbone, M.D. Associate Director for Research.

Laurie E. Locascio, Ph.D. Director, MML/NIST NIST/MML: Measurement Assurance for Biological Systems.

RC ICT Conference 17 May 2004 Research Councils ICT Conference The UK e-Science Programme David Wallace, Chair, e-Science Steering Committee.

Recent Studies Funded by the Progressive MS Alliance Tim Coetzee, PhD ACTRIMS 2016.

Uses of the NIH Collaboratory Distributed Research Network Jeffrey Brown, PhD for the DRN Team Harvard Pilgrim Health Care Institute and Harvard Medical.

1 LS DAM Overview August 7, 2012 Current Core Team: Ian Fore, D.Phil., NCI CBIIT, Robert Freimuth, Ph.D., Mayo Clinic, Mervi Heiskanen, NCI-CBIIT, Joyce.

BioMarker Strategies biotrinity 2016 London April Functional Profiling to Guide Cancer Drug Development and Treatment Selection.

NCI Division of Cancer Prevention Ongoing Activities at Frederick Facilities Presented By: Lori Minasian, M.D. Robert Shoemaker, Ph.D. October 1, 2015.

RAS Initiative at the Federally Funded Research and Development Center at Frederick Presented By: Sara S. Hook October 1, 2015.

I farmaci innovativi in una prospettiva europea Giuseppe M.C. Rosano, MD, PhD Cardiovascular and Cell Sciences Research Institute, St George's University.

Interagency Oncology Task Force (IOTF)

Pediatric Preclinical Testing Consortium

Cancer Center: A Pathway to Collaborative Research and NCI Designation Mark Reeves, MD, PhD, Cancer Center Director 2016 Research Symposium, 10/21/16.

Yale SPORE in Skin Cancer

Accelerating Precision Medicine for Advanced Cancer Patients

Clinical Trials in STS Shreyaskumar Patel, M.D.

Introduction to TransCelerate

Pediatric Preclinical Testing Consortium

SARC003: Phase II Study of Gemcitabine & Docetaxel in Recurrent Ewings Sarcoma, Osteosarcoma, or Unresectable/Locally Recurrent Chondrosarcoma Elizabeth.

CBTTC Fiscal Year 18 Strategic Objectives

Quality and Process Improvement Program (QPIP)

Trial Funding and Engagement: The NIH Sponsored CTSA Program

Cancer is a Challenge Cancer is common in humans – a public health problem ~1 of every 3 women will develop cancer ~1 of every 2 men will develop cancer.

The Cancer genome atlas (TCGA) and the search for a CUP genetic/epigenetic signature Manel Esteller, MD, PhD. Director, Josep Carreras Leukaemia Research.

The FaceBase Consortium

Patient Engagement through Social Media for Clinical Trials

Center for Clinical and Translational Science

Presentation transcript:

SARC Developmental Therapeutics Committee Update Chand Khanna Open Science: Biology to Therapy” SARC Developmental Therapeutics Committee Update Chand Khanna Chawla/Rosenfeld Developmental Therapeutics Symposium “Open Science: Biology to Therapy” SARC Developmental Therapeutics

SARC-DTC Members Chand Khanna, DVM, PhD (NCI) Chair Poul Sorenson, MD, PhD (UBC/BC Cancer Agency) Raphael Pollock, MD, PhD (MD Anderson) Kapil Dhingra, MD (KAPital Consulting) Jeffrey Trent, PhD (Tgen) David Kirsch, MD, PhD (Duke University) Peter Houghton, PhD (Ohio State University) *Shreyaskumar Patel, MD (MD Anderson) *Denise Reinke, MS, NP (SARC) *Ex Officio

SARC Developmental Therapeutics Committee (DTC To establish an integrated and facile SARC effort closely aligned with the interests of pharmaceutical industry that can provide preclinical and translational data in sarcoma

SARC – Development Therapeutics Committee Investigative Centers Providing SARC-DTC Services Sponsoring Pharmaceutical Partner Investigative Centers defined through SARC- DTC Investigative Centers engaged by SARC-DTC through Master Services Agreement SARC-DTC work scope managed through a research contract with Sponsors SARC-DTC Preclinical and Translational Study Report SARC-DTC Preclinical and Translational Infrastructure

SARC – Development Therapeutics Committee Investigative Centers Providing SARC-DTC Services Investigative Centers defined through SARC- DTC Investigative Centers engaged by SARC-DTC through Master Services Agreement SARC-DTC Preclinical and Translational Infrastructure Current Investigative Center Portfolio >50 Sarcoma Cell Lines >30 Sarcoma Xenografts  Sarcoma tissues Frozen tissues Sarcoma Tissue Arrays Genomics (SARComics Portal)

SARC-DTC Preclinical and Translational Infrastructure  Expansion of drug opportunities/assets for SARC clinical development through the development of preclinical and translational data in sarcoma  Prioritization of SARC developmental path  Opportunity to inform phase 1 and phase 2 transitions within SARC clinical development path  Please help spread the word to interested parties of the opportunities to generate preclinical data in sarcoma through SARC

SARC-Omics Portal  To provide sarcoma investigators a consolidated portal for curation and viewing of “omics” data.  To be developed through a collaboration of TGEN and SARC  Screen shots expected at the SARC/CTOS 2013 in a matter of minutes…

SARC Developmental Therapeutics Committee Update Chand Khanna SARC Developmental Therapeutics Committee Update Chand Khanna Chawla/Rosenfeld Developmental Therapeutics Symposium Chawla/Rosenfeld Developmental Therapeutics Symposium

Chawla Rosenfeld Developmental Therapeutics Symposium Open Science: Biology to Therapy A Case for Open-Source Drug Discovery – J. Bradner Anti-angiogenic activity of JQ1 in Sarcomas – H. Bid The Sarcoma Data Portal: Making High Content Sarcoma Datasets Available For All Users – J. Keats Discussion (20 min)